Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a UK patent has been filed for the use of a combination of biomarkers for improved cancer prognosis testing. This technology will be included in OCB’s ColoProg test which will allow surgeons and oncologists to better target adjuvant chemotherapy, to those individuals at highest risk of relapse and avoid chemotherapy in patients who have a high likelihood of cure by surgery alone.
David Kerr, CMO of Oxford Cancer Biomarkers, commented: “The protection of new IP is a key step in being able to strengthen OCB’s proprietary position for the ColoProg test. The ColoProg test has been developed to be seamlessly inserted into current clinical pathways for colorectal cancer and provides important information to treating oncologists. The protected IP should be translatable to other disease indications further strengthening OCBs commercial potential.”
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.
For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743